Opinion|Videos|February 27, 2025
Balancing Treatment Intensity and Resistance Mechanisms in First-Line EGFR-mutated NSCLC: Amivantamab + Lazertinib vs Osimertinib Monotherapy
Author(s)Misako Nagasaka, MD, PhD
The panelist discusses how, Healthcare professionals use osimertinib 1L for EGFR-mutated NSCLC, re-testing at progression for resistance mutations. MARIPOSA data refine 1L choices by predicting resistance pathways, guiding optimal sequencing.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- What is your sequencing strategy/rationale for 1L and beyond in EGFR-mutated metastatic NSCLC?
- When would you re-test for new resistance mutations?
- How does recent evidence from MARIPOSA (resistance mechanisms analysis) influence what you would use upfront in 1L treatment?
Advertisement
Related to this article
The FDA communicated that the phase 2 IDeate-Lung01 results were not sufficient for an accelerated approval of I-DXd in small cell lung cancer.
The phase 2 ALISCA-Lung2 trial (PUMA-ALI-4202) is exploring alisertib plus paclitaxel in small cell lung cancer after immunotherapy and chemotherapy.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Plinabulin Receives FDA Fast Track Designation in Post-ICI NSCLC
2
FDA Oncology Recap: Approvals, Designations, and Decisions in September 2026
3
Denosumab Biosimilar Approved For Existing Oncology Indications
4
CEPHEUS and Frontline Treatment in Newly Diagnosed Multiple Myeloma
5